Combined Aspirin-oral Anticoagulant Therapy Compared with Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease: a Meta-analysis of Randomized Trials.
From: Department of Medicine, McMaster University, and St Joseph’s Healthcare, Hamilton, Ontario, Canada.
Archives of internal medicine
- Publish Date: Jan 2007
- ISSN: 0003-9926
- Volume: 167
- Issue: 2
- Pages: 117-24
- Medium: Print
- Language: English
- Citation (JAMA): Dentali Francesco, Douketis James D, Lim Wendy, et al. Combined Aspirin-oral Anticoagulant Therapy Compared with Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease: a Meta-analysis of Randomized Trials.. Arch. Intern. Med. Jan 2007;167:117-24
Abstract
BACKGROUND: For patients receiving oral anticoagulant (OAC) therapy, deciding whether to add aspirin to their treatment is a common clinical scenario with no clear guidelines to aid practice. We performed a systematic review and meta-analysis of randomized controlled trials comparing these 2 treatment strategies (combined aspirin-OAC therapy vs OAC therapy alone) to assess the therapeutic benefits and risks. DATA SOURCES: Randomized controlled trials published up to June 2005 in MEDLINE, EMBASE, and Cochrane Library databases. STUDY SELECTION: Randomized controlled trials with at least 3 months of follow-up that compared aspirin-OAC therapy with OAC therapy alone, in which OAC was administered to achieve the same target international normalized ratio or was given at the same fixed dose in both treatment arms. DATA EXTRACTION: Two reviewers independently extracted data on study characteristics and outcomes. Pooled odds ratios (ORs) and associated 95% confidence intervals (CIs) were calculated for study outcomes in patients receiving aspirin-OAC therapy and OAC therapy alone. DATA SYNTHESIS: Ten studies were included, totaling 4180 patients. The risk for arterial thromboembolism was lower in patients receiving combined aspirin-OAC therapy compared with OAC therapy alone (OR, 0.66; 95% CI, 0.52-0.84). However, these benefits were limited to patients with a mechanical heart valve (OR, 0.27; 95% CI, 0.15-0.49). There was no difference in the risk for arterial thromboembolism with these treatments in patients with atrial fibrillation (OR, 0.99; 95% CI, 0.47-2.07) or coronary artery disease (OR, 0.69; 95% CI, 0.35-1.36). There was no difference in all-cause mortality with either treatment (OR, 0.98; 95% CI, 0.77-1.25). The risk for major bleeding was higher in patients receiving aspirin-OAC therapy compared with OAC therapy alone (OR, 1.43; 95% CI, 1.00-2.02). CONCLUSION: Our findings question the current practice of using combined aspirin-OAC therapy except in patients with a mechanical heart valve, given the questionable benefits in reducing thromboembolic events and the increased risk of major bleeding.
Mesh Headings (Keywords): Administration, Oral, Anticoagulants, Aspirin, Drug Therapy, Combination, Heart Valve Prosthesis, Hemorrhage, Humans, Mortality, Platelet Aggregation Inhibitors, Randomized Controlled Trials as Topic, Risk Factors, Thromboembolism
Check for Full Text / PubMed Unique Identifier (PMID): 17242311
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.